Reimbursement

reimbursement hub home

CMS Requires More

NaF-18 PET Data

1
Select your area of interest
2
Contact details

We are always interested in engaging with you.

Let us know how we can help.

1
2
Contact details

Submit a sales inquiry

Please provide some information below and we can help direct you to the right person
We work with partners and distributors who may contact you about this Philips product on our behalf.
*
*
*
*
*
*
*
*

Philips values and respects the personal information of its customers. You may revoke the permissions you grant at any time. See the Philips Privacy Policy for more information.
Les informations collectées sont enregistrées par Philips France Commercial, 33 rue de Verdun 92150 Suresnes. Vos données seront conservées en dehors de l’Union Européenne et utilisées par les services marketing de Philips pour une durée de 24 mois à compter de leur collecte ou du dernier contact de votre part. Conformément à la loi n°78-17 Informatique et Libertés modifiée et au Règlement européen n° 2016/679 vous bénéficiez, sur les données personnelles qui vous concernent, d’un droit d’accès et de rectification et, s'ils sont applicables, d'un droit de suppression, d’opposition, d'effacement, de limitation du traitement, et de portabilité. Vous pouvez exercer ces droits en vous adressant à : privacy@philips.com en fournissant un justificatif d'identité. Vous pouvez également définir des directives relatives au sort de vos données après votre décès et introduire une réclamation auprès de la CNIL. 

September 21, 2015

 

The Center for Medicare & Medicaid Services has proposed to continue for one year its coverage of Sodium Fluoride F-18 ( NaF-18) PET for bone metastases of cancer when data on its use are included in a clinical data registry. The agency says that this should be enough time for additional analyses to determine if such scans change how physicians manage patients and improve survival or quality of life.

 

The agency agreed in 2010 to cover such scans under its coverage with evidence development program, which required collection of data on the use of the scans in a clinical registry. Through 2014, the registry had collected data from 35,468 scans performed on 28,713 patients. The physicians who directed the registry requested earlier this year that CMS lift its data reporting requirement because the large volume of data already collected demonstrated the value of using the procedure in guiding cancer care.

 

CMS said it would reconsider its proposed decision after the additional analyses are published. The agency is seeking comments on the proposed decision.

 

Read CMS Proposed Decision Memo